Crossref
Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
Cancer and Clinical Oncology · 2012
DOI: 10.5539/cco.v1n2p25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer and Clinical Oncology, 2012. Verfasst von Jose María Vieitez und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Vieitez, J. M., Fonseca, P. J., Berros, J. P., Sanmamed, M. F. D., Restrepo, E. G., Izquierdo, M., Pardo, P., & Lacave, A. J. (2012). Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology. https://doi.org/10.5539/cco.v1n2p25
Vancouver
Vieitez JM, Fonseca PJ, Berros JP, Sanmamed MFD, Restrepo EG, Izquierdo M, et al. Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology. 2012. doi:10.5539/cco.v1n2p25
BibTeX
@article{Vieitez2012,
author = {Vieitez, Jose María and Fonseca, Paula J. and Berros, Jose P. and Sanmamed, Miguel Fernandez De and Restrepo, Eduardo Gutierrez and Izquierdo, Marta and Pardo, Pablo and Lacave, Angel J.},
title = {Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer},
journal = {Cancer and Clinical Oncology},
year = {2012},
doi = {10.5539/cco.v1n2p25}
}
EUVIMED